GSK's blockbuster hope darapladib crashes in Ph III
This article was originally published in Scrip
Executive Summary
Darapladib, GlaxoSmithKline's investigative pill for reducing cardiovascular events in patients with coronary heart disease, has failed to meet the primary endpoint in the first of two major Phase III studies. It continues to be studied in a separate Phase III trial for acute coronary syndrome.